COMMUNIQUÉS West-GlobeNewswire

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
03/06/2026
BEIJING, June 02, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that updated data [...]
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
03/06/2026
Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN ® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating [...]
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
03/06/2026
- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucocorticoid-related [...]
DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide
03/06/2026
Châtillon, France, le 02 juin (22 :30 CEST) 2026 DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN ® Peanut chez les nourrissons âgés de 6 à 12 mois [...]
Fortrea to Attend Jefferies Global Healthcare Conference
03/06/2026
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor [...]
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
02/06/2026
Management to host webcast on Wednesday, June 3 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a [...]
Alvotech to present at upcoming investor conferences in June
02/06/2026
REYKJAVIK, Iceland, June 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for [...]
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
02/06/2026
New 7-Laser Cytek Borealis™ System With Deep Ultraviolet and Infrared cFluor® Reagents; Cytek Aurora™ Evo System Enhancements for Automation and Workflow Efficiency FREMONT, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- At [...]
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June [...]
INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q
02/06/2026
SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
Neuronetics Appoints Robert Greene as Senior Vice President Sales
02/06/2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who [...]
Shopify Announces $3 Billion Increase to Share Repurchase Program
02/06/2026
Internet, Everywhere, June 02, 2026 (GLOBE NEWSWIRE) -- Shopify Inc. (NASDAQ, TSX: SHOP) today announced that its Board of Directors has authorized an additional $3 billion for the repurchase of Class A subordinate [...]
CAHI Honours The Honourable Don Boudria for Leadership in Animal Health
02/06/2026
OTTAWA, Ontario, June 02, 2026 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is proud to announce the recipients of its 2026 Annual Awards, recognizing exceptional leadership and contributions to [...]
Crescent Biopharma to Present at June Investor Conferences
02/06/2026
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
L’ICSA rend hommage à l’honorable Don Boudria pour son engagement envers la santé animale
02/06/2026
OTTAWA, Ontario, 02 juin 2026 (GLOBE NEWSWIRE) -- L’Institut canadien de la santé animale (ICSA) est fier d’annoncer les lauréats de ses prix annuels 2026, qui récompensent un engagement et des contributions [...]
Onco360® Has Been Selected as a National Specialty Pharmacy Provider for IMKELDI® (imatinib) Oral Solution
02/06/2026
LOUISVILLE, KY, June 02, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Shorla Oncology for IMKELDI ® (imatinib) Oral Solution, [...]
Alvotech to present at upcoming investor conferences in June
02/06/2026
REYKJAVIK, ICELAND (June 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
02/06/2026
Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company’s other platforms New data from [...]

Pages